• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Safety of pre-emptive donor lymphocyte infusions (DLI) based on mixed chimerism (MC) in peripheral blood or bone marrow subsets in children undergoing hematopoietic stem cell transplant (HSCT) for hematologic malignancies.

作者信息

Liou A, Wahlstrom J T, Dvorak C C, Horn B N

机构信息

Department of Pediatrics, Benioff Children's Hospital, University of California, San Francisco, CA, USA.

Division of Pediatric Blood and Marrow Transplantation, Benioff Children's Hospital, University of California, San Francisco, CA, USA.

出版信息

Bone Marrow Transplant. 2017 Jul;52(7):1057-1059. doi: 10.1038/bmt.2017.45. Epub 2017 Apr 10.

DOI:10.1038/bmt.2017.45
PMID:28394367
Abstract
摘要

相似文献

1
Safety of pre-emptive donor lymphocyte infusions (DLI) based on mixed chimerism (MC) in peripheral blood or bone marrow subsets in children undergoing hematopoietic stem cell transplant (HSCT) for hematologic malignancies.基于混合嵌合体（MC）的先发制供体淋巴细胞输注（DLI）在接受血液系统恶性肿瘤造血干细胞移植（HSCT）的儿童外周血或骨髓亚群中的安全性。
Bone Marrow Transplant. 2017 Jul;52(7):1057-1059. doi: 10.1038/bmt.2017.45. Epub 2017 Apr 10.
2
Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies.基于嵌合体的抢先免疫疗法，用于小儿血液系统恶性肿瘤的异基因干细胞移植后快速停用免疫抑制剂及输注供体淋巴细胞。
Biol Blood Marrow Transplant. 2015 Apr;21(4):729-37. doi: 10.1016/j.bbmt.2014.12.029. Epub 2015 Jan 31.
3
Donor Lymphocyte Infusions Used to Treat Mixed-Chimeric and High-Risk Patient Populations in the Relapsed and Nonrelapsed Settings after Allogeneic Transplantation for Hematologic Malignancies Are Associated with High Five-Year Survival if Persistent Full Donor Chimerism Is Obtained or Maintained.在血液系统恶性肿瘤异基因移植后复发和未复发的情况下，使用供者淋巴细胞输注治疗混合嵌合体和高危患者人群，如果持续获得或维持完全供者嵌合体，则与高五年生存率相关。
Biol Blood Marrow Transplant. 2017 Nov;23(11):1989-1997. doi: 10.1016/j.bbmt.2017.07.007. Epub 2017 Jul 13.
4
Peripheral blood late mixed chimerism in leucocyte subpopulations following allogeneic stem cell transplantation for childhood malignancies: does it matter?儿童恶性肿瘤异基因干细胞移植后白细胞亚群中的外周血晚期混合嵌合现象：这重要吗？
Br J Haematol. 2016 Jun;173(6):905-17. doi: 10.1111/bjh.14008. Epub 2016 Mar 21.
5
Comparison of second transplantation and donor lymphocyte infusion for donor mixed chimerism after allogeneic stem cell transplantation for nonmalignant diseases.非恶性疾病异基因干细胞移植后二次移植与供体淋巴细胞输注对供体混合嵌合体的比较。
Pediatr Blood Cancer. 2016 Dec;63(12):2221-2229. doi: 10.1002/pbc.26141. Epub 2016 Aug 24.
6
Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases.在为患有非恶性疾病的儿科患者采用低强度预处理方案后，供体淋巴细胞输注治疗混合供体嵌合状态的结果。
Biol Blood Marrow Transplant. 2015 Feb;21(2):288-92. doi: 10.1016/j.bbmt.2014.10.010. Epub 2014 Oct 18.
7
Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后供体白细胞输注的高严格性CD8细胞清除的I期研究
Transplantation. 2009 Dec 15;88(11):1312-8. doi: 10.1097/TP.0b013e3181bbf382.
8
The value of donor lymphocyte infusions in thalassemia patients at imminent risk of graft rejection following stem cell transplantation.干细胞移植后即将发生移植物排斥的地中海贫血患者中供者淋巴细胞输注的价值。
Pediatr Blood Cancer. 2012 Mar;58(3):453-8. doi: 10.1002/pbc.23350. Epub 2011 Oct 11.
9
Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation.供体嵌合现象并不能预测异基因造血细胞移植后复发的慢性粒细胞白血病对供体淋巴细胞输注的反应。
Biol Blood Marrow Transplant. 2004 Mar;10(3):171-7. doi: 10.1016/j.bbmt.2003.10.004.
10
Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions.白血病谱系特异性嵌合体分析和分子监测可改善供者淋巴细胞输注的疗效。
Biol Blood Marrow Transplant. 2010 Dec;16(12):1728-37. doi: 10.1016/j.bbmt.2010.06.005. Epub 2010 Jun 10.

引用本文的文献

1
Optimizing Blood Stem Cell Transplants Through Cellular Engineering.通过细胞工程优化造血干细胞移植
Blood Cell Ther. 2022 Jan 14;5(1):1-15. doi: 10.31547/bct-2021-008. eCollection 2022 Feb 25.
2
A practical guide to chimerism analysis: Review of the literature and testing practices worldwide.嵌合体分析实用指南：文献回顾与全球检测实践。
Hum Immunol. 2021 Nov;82(11):838-849. doi: 10.1016/j.humimm.2021.07.013. Epub 2021 Aug 14.
3
Donor-Host Lineage-Specific Chimerism Monitoring and Analysis in Pediatric Patients Following Allogeneic Stem Cell Transplantation: Influence of Pretransplantation Variables and Correlation with Post-Transplantation Outcomes.

本文引用的文献

1
IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.异基因移植前及移植后早期的免疫球蛋白重链可变区（IgH）-V（D）J下一代测序微小残留病（NGS-MRD）检测可明确极低风险和极高风险的急性淋巴细胞白血病（ALL）患者。
Blood. 2015 May 28;125(22):3501-8. doi: 10.1182/blood-2014-12-615757. Epub 2015 Apr 10.
2
Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies.基于嵌合体的抢先免疫疗法，用于小儿血液系统恶性肿瘤的异基因干细胞移植后快速停用免疫抑制剂及输注供体淋巴细胞。
Biol Blood Marrow Transplant. 2015 Apr;21(4):729-37. doi: 10.1016/j.bbmt.2014.12.029. Epub 2015 Jan 31.
3
异基因造血干细胞移植后供受者谱系嵌合体监测与分析：移植前变量的影响及其与移植后结局的相关性。
Transplant Cell Ther. 2021 Sep;27(9):780.e1-780.e14. doi: 10.1016/j.jtct.2021.05.020. Epub 2021 May 31.
Risk-adapted donor lymphocyte infusion based on chimerism and donor source in pediatric leukemia.基于嵌合状态和供者来源的风险适应性供者淋巴细胞输注在儿科白血病中的应用。
Blood Cancer J. 2013 Aug 30;3(8):e137. doi: 10.1038/bcj.2013.39.
4
Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation.风险分层指导下的供者淋巴细胞输注可降低异基因造血干细胞移植后标准风险急性白血病患者的复发率。
Blood. 2012 Apr 5;119(14):3256-62. doi: 10.1182/blood-2011-09-380386. Epub 2012 Feb 14.
5
Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation.异基因干细胞移植后出现混合嵌合体证据的儿童急性髓细胞白血病的抢先免疫治疗。
Blood. 2011 Nov 17;118(20):5681-8. doi: 10.1182/blood-2011-04-348805. Epub 2011 Sep 26.
6
Feasibility study of preemptive withdrawal of immunosuppression based on chimerism testing in children undergoing myeloablative allogeneic transplantation for hematologic malignancies.基于嵌合体检测对接受清髓性异基因造血干细胞移植治疗血液系统恶性肿瘤的儿童进行免疫抑制预撤减的可行性研究。
Bone Marrow Transplant. 2009 Mar;43(6):469-76. doi: 10.1038/bmt.2008.339. Epub 2008 Oct 27.
7
Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?混合嵌合体增加是急性淋巴细胞白血病儿童异基因干细胞移植后不良预后的重要预后因素：抢先免疫疗法的可能作用？
J Clin Oncol. 2004 May 1;22(9):1696-705. doi: 10.1200/JCO.2004.05.198.
8
Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation.供体淋巴细胞输注用于治疗异基因血液或骨髓移植后复发的血液系统恶性肿瘤。
Cancer Control. 2002 Mar-Apr;9(2):123-37. doi: 10.1177/107327480200900205.
9
Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.慢性髓性白血病异基因干细胞移植后复发患者接受供体淋巴细胞输注后的反应持久性
Blood. 2000 Oct 15;96(8):2712-6.
10
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.供体淋巴细胞输注对骨髓移植患者的移植物抗白血病效应
Blood. 1995 Sep 1;86(5):2041-50.